The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.

Jia Zhou, Fei Dong, Fang Cui, Rui Xu, Xiaokui Tang,


Cancer chemotherapy and pharmacology, March 14, 2017


Non-small-cell lung cancer (NSCLC) lacks validated biomarkers to predict the prognosis and treatment response. This study investigated whether circulating tumor cells (CTCs) detectable could reminder high risk of distant metastasis, provide prognostic information, and early indicate the response to the conventional therapy in patients with advanced NSCLC. In this single-center prospective study, blood samples for CTC analysis were obtained from 59 patients with previously untreated, stage III or IV NSCLC both before and after administration of two cycles of chemotherapy. CTCs took in peripheral blood were measured by Cell Search detect technique. Carcino-embryonic antigen and count of metastatic sites were positively related to CTC count analyzed by multiple linear regression (P 


Pubmed Link: 28289866

DOI: 10.1007/s00280-017-3269-x